Last reviewed · How we verify
BT062
At a glance
| Generic name | BT062 |
|---|---|
| Also known as | Indatuximab ravtansine |
| Sponsor | Biotest Pharmaceuticals Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma (PHASE1, PHASE2)
- Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT062 CI brief — competitive landscape report
- BT062 updates RSS · CI watch RSS
- Biotest Pharmaceuticals Corporation portfolio CI